In relapsed or refractory high-risk neuroblastoma (HRNB)
in the bone and/or bone marrowYou support your
child,
let DANYELZA
support
you along
the way
Availability & Financial Support
DANYELZA treatment availability is expanding every day
DANYELZA is offered at many treatment centers across the United States, and you may be able to get it without traveling from your home hospital.
In the event your home hospital does not currently offer DANYELZA®, use our map to find the treatment center* nearest to you. Note the listed centers are only those that have authorized their participation on this website. Please check back regularly for updates.
Enter a city, state, or ZIP code:
Get Your Directions
LOCATE YOUR GEOPOSITION
Directions
The contact information for these treatment centers is provided as a courtesy, and it is not intended as an endorsement or recommendation of any healthcare provider/treatment center. Y-mAbs® Therapeutics does not make any representations or guarantees about the qualifications, competence, or skills of any healthcare provider/treatment center, the accuracy of any diagnosis, or the appropriateness of any treatment that a healthcare provider may prescribe or recommend. Patients should make their own, independent decisions regarding the capabilities and suitability of potential healthcare providers/treatment centers, and Y-mAbs does not play a role in any patient-provider relationship you may establish.
Y-mAbs Therapeutics is dedicated to helping qualifying patients access DANYELZA
Y-mAbs Connect® is a patient support program that provides information about access, insurance, potential financial support, and other resource programs for enrolled patients who may qualify.
Our dedicated team of case managers can:
- Help you understand your child’s insurance benefits and out-of-pocket costs for DANYELZA®
- Provide information about third-party organizations that may offer support for travel to infusion site and lodging costs*
- Help you determine if you may qualify for Y-mAbs Connect financial support programs
Third-party organizations are not associated with Y-mAbs Therapeutics, Inc.; specific details and eligibility requirements may vary by organization.
How to enroll
If your child was prescribed DANYELZA, your healthcare provider can complete the Y-mAbs Connect enrollment form with you and return it by fax, mail, or email. A Y-mAbs Connect case manager will contact you once you have been enrolled.
For more information and to download the enrollment form, visit ymabsconnect.com.
Y-mAbs Connect Financial Support Programs
Y-mAbs Connect Co-pay Program
- For eligible individuals with
commercial or private insurance - May help reduce out-of-pocket costs of
DANYELZA to $0 for eligible patients
Y-mAbs Connect Patient Assistance Program (PAP)
- For eligible individuals who are uninsured or are rendered underinsured for DANYELZA through their health plan
- May be able to provide DANYELZA
at no cost
Information about Y-mAbs Connect can be found at ymabsconnect.com
or by calling Y-mAbs Connect 1-833-33YMABS (1-833-339-6227)
Monday through Friday, 8 AM to 8 PM
Caregiver Tools
Resources to help you feel ready
Caregiver Brochure
Advocacy, Research, & Support Groups
HRNB can feel all-consuming, but we're here with support and resources you can count on
Neuroblastoma support groups
Providing you with information, logistical assistance, and emotional support throughout your neuroblastoma treatment journey
Educational Support
Arms Wide Open Childhood Cancer Foundation
awoccf.orgThe Arms Wide Open Childhood Cancer Foundation is committed to funding pediatric cancer research, supporting families, both financially and emotionally, educating the general public, raising awareness, uniting the childhood cancer community, giving children with cancer a platform to share their voice, and working to ensure children who survive childhood cancer thrive.
Children’s Neuroblastoma Cancer Foundation (CNCF)
cncfhope.orgThe premier source for neuroblastoma information and resources, the CNCF is composed of families like yours committed to finding a cure for neuroblastoma through research, education, awareness, and advocacy.
The EVAN Foundation
theevanfoundation.orgSpreads smiles and hope, and drives change in the fight against neuroblastoma.
Isabella Santos Foundation (ISF)
isabellasantosfoundation.orgEstablished in memory of Isabella Santos, whose dream was to beat cancer, grow her hair, and live her dreams. ISF is dedicated to improving rare pediatric cancer treatment options to increase survival rates of kids with cancer.
Solving Kids’ Cancer
solvingkidscancer.orgFocuses on aggressive childhood cancers with low survival rates by helping accelerate new, next-generation treatments.
Research Groups & Resources
CAC2 Kids’ Cancer Research Foundation
cac2.orgCoalition Against Childhood Cancer (CAC2) is a collaborative network of international nonprofits, corporations, and individuals that advance a variety of childhood cancer causes.
Clinicaltrials.gov
clinicaltrials.govA database of privately and publicly funded clinical studies conducted around the world. Individuals can search key terms, such as "neuroblastoma."
National Cancer Institute (NCI)
cancer.gov/about-nciThe federal government’s principal agency for cancer research and training.
New Approaches to Neuroblastoma Therapy (NANT)
nant.orgEstablished in 2000, NANT is the only international clinical trials consortium focused on developing new treatments and biomarkers for relapsed/refractory high-risk neuroblastoma to improve outcome. High-risk neuroblastoma remains a challenge, despite improvements seen with intensive chemotherapy, isotretinoin, and immunotherapy.
FAQ & Glossary
Who is DANYELZA for?
DANYELZA® is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:
- has come back (relapsed) or that did not respond to previous treatment (refractory), and
- has shown a partial response, minor response, or stable disease to prior therapy.
It is not known if DANYELZA is safe and effective in children younger than 1 year of age.
Is DANYELZA known by any other names?
The established name for DANYELZA is naxitamab-gqgk. You may also hear it referred to as Hu3F8 because that is what it was called when it was being studied in one of the clinical trials.
What are the 3 key things I should know about DANYELZA?
Used in combination with another medicine called GM-CSF, DANYELZA is the ONLY FDA-approved immunotherapy for HRNB that:
- Is specifically for RELAPSED or REFRACTORY disease in the bone or bone marrow after a partial response, minor response, or stable disease
- Is HUMANIZED, or made to more closely resemble antibodies found in the human body
- Has the option to be administered in an OUTPATIENT setting, based on what your child’s doctor decides. This means you and your child may be able to go home on a treatment day
What results can I expect with DANYELZA?
Everyone responds to medicines differently; you can learn all about how DANYELZA performed in a clinical trial by visiting our Treatment With DANYELZA page.
How is DANYELZA given?
DANYELZA is given intravenously (IV) by a team of healthcare professionals who will monitor your child closely throughout the infusion. It is also given with another medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF can be given at home and starts 5 days before the first DANYELZA infusion.
How long does each DANYELZA infusion last?
On Day 1 of Cycle 1, the DANYELZA infusion will be 60 minutes, as tolerated. The rest of the DANYELZA infusions will be 30-60 minutes, as tolerated.
Will my child have to stay overnight at the hospital?
DANYELZA was studied in an outpatient setting, which may give your child the option of doing inpatient or outpatient treatment. Your child’s doctor will decide which is most appropriate for your child.
How many treatment cycles of DANYELZA will my child have to do?
Since every child is different, it’s difficult to know exactly how many treatment cycles your child may need. Once your child’s doctor sees an initial response to treatment, DANYELZA will be given for another 5 cycles every 4 weeks. From there, your doctor may repeat treatment cycles every 8 weeks.
Your child’s doctor will continue monitoring your child’s response to determine if treatment should continue. They will stop treatment if your child’s disease progresses or if they cannot tolerate the side effects.
What are some of the side effects associated with DANYELZA?
Signs and symptoms of infusion-related reactions during or after DANYELZA treatment include:
- Swelling of the face, eyes, lips, mouth, or tongue
- Itching
- Redness of the face
- Skin rash or hives
- Trouble breathing
- Coughing or wheezing
- Noisy, high-pitched breathing
- Feeling faint or dizzy
DANYELZA can also cause nervous system problems such as severe pain from nerves (neuropathic pain), including pain in the belly (abdomen), bone, neck, legs, or arms. Pain is common with DANYELZA and can be severe.
Other nervous system problems include:
- Inflammation of the spinal cord
- Reversible Posterior Leukoencephalopathy Syndrome (RPLS – also known as Posterior Reversible Encephalopathy Syndrome - PRES), which is a condition of the brain
- Numbness, tingling, or burning sensation in the arms or legs
- Nervous system problems of the eye
- Problems urinating or emptying your bladder (prolonged urinary retention)
How are side effects managed?
Your child will be closely monitored by their care team for side effects throughout treatment. This will happen whether they receive DANYELZA in an inpatient or an outpatient setting.
There are recommendations that your child’s care team will follow to help manage side effects. Your child’s care team will give your child certain medicines before and during DANYELZA infusions to help manage pain and infusion-related reactions.
I am worried about planning to have to travel for treatment. Can someone help me with this?
See our list of third-party community groups who can provide you with logistical assistance.
Note: Third-party organizations are not associated with Y-mAbs® Therapeutics, Inc.; specific details and eligibility requirements may vary by organization.
Will my insurance cover DANYELZA?
Many do, but every insurance plan is different. Speak with a Y-mAbs Connect case manager to help confirm your eligibility by calling 1-833-33YMABS (1-833-339-6227), option 2, Monday through Friday (8 AM to 8 PM ET).
I would love to hear what other caregivers have to say about DANYELZA. Where can I find these insights?
You can engage with stories of caregivers who have been through DANYELZA treatment with their child, and learn some tips for self-care, by visiting our Caregiver Experience page.
Do you have an email list?
Yes! By joining our email list, you can stay up to date on information about treatment with DANYELZA.
Important terms for understanding DANYELZA
-
Antibody
An antibody is a protein made by white blood cells in response to a foreign substance in the body. This substance, called an antigen, causes an immune response in the body. Each antibody is made to bind to one specific type of antigen and destroy it. Antibody therapies use antibodies to help the body fight cancer, infection, or other diseases.
-
Anti-drug antibody
An antibody that binds to a specific drug.
-
Bone marrow
Bone marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.
-
Complete response
A complete response, or CR, is when the patient showed no physical evidence of disease on examination or imaging tests after treatment. Complete response is sometimes phrased as “no evidence of disease” and abbreviated NED.
-
Consolidation therapy
Consolidation therapy is used to kill any cancer cells that may be left in the body after initial chemotherapy. Consolidation can include treatments like chemotherapy, radiation, stem cell transplant, etc.
-
Curie score
A numbering system that divides the body into 9 skeletal sections with a tenth soft-tissue section that measures the extent of neuroblastoma still present in the body.
-
Duration of response (DOR)
The amount of time patients maintain their complete or partial response, without the cancer growing or spreading.
-
Efficacy
The measurement of how well a medicine works to produce a desired effect.
-
GD2
GD2 is a molecule found on neuroblastoma cells and certain nerve cells.
-
GM-CSF
Granulocyte-macrophage colony-stimulating factor is a medication given with DANYELZA to help the body’s immune system during cancer treatment.
-
High-risk
Neuroblastoma is considered high risk when the cancer cannot be surgically removed and has spread to other parts of the body.
-
Humanized
Humanized is a way of describing immunotherapies that are made to more closely resemble antibodies that are naturally present in the human body.
-
Immune system
The immune system is made up of all the cells, tissues, organs, and the substances they make that help the body fight infections and other diseases.
-
Immunotherapy
Immunotherapy is a type of medicine that uses substances to stimulate or suppress the immune system to help the body fight a disease.
-
Incomplete response
This may refer to: stable disease, when the cancer stays the same; partial response, when the cancer is reduced in all places it was originally present; and minor response, when the cancer is reduced in some places but not all.
-
Induction therapy
Induction therapy is an initial attempt to treat the cancer and often includes chemotherapy and surgery.
-
Infusion
An infusion is a way to put fluids, including drugs, into the bloodstream. It is often called an intravenous infusion, which means an infusion into a vein.
-
IV (intravenous)
IV is short for intravenous and usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein.
-
Maintenance therapy
Maintenance therapy is the attempt to treat the cancer throughout the body with medications after initial treatment. These medications may include chemotherapy, hormonal therapy, targeted therapy, or immunotherapy.
-
MIBG scan
A meta-iodobenzylguanidine (MIBG) scan is a procedure that helps detect the presence of neuroblastoma and its location in the body.
-
Outpatient
Outpatient refers to medical care that can be completed without a patient staying in a hospital overnight.
-
Overall response rate (ORR)
Overall response rate is the percentage of patients in a study who have either a complete or partial response to treatment.
-
Partial response (PR)
A partial response is when a patient’s cancer is reduced in all places originally present.
-
Refractory
Refractory is a term used to describe cancer that does not respond completely to initial treatment.
-
Relapsed
Relapsed is a term used to describe cancer that has returned following a complete response to previous treatment.
-
Remission
Remission is a decrease or disappearance of cancer signs and symptoms.
-
Subcutaneous injection
A subcutaneous injection is a method of delivering a medication with a needle that is inserted into the tissue between skin and muscle.
-
Targeted therapy
Treatments designed to find and attack cancer cells; aiming to stop their growth or kill them by targeting things common on the tumor and less common in normal tissue.